The USAMRMC develops, acquires, provides, and sustains world-class solutions and capabilities to enable medical readiness globally. Under the contract, Leidos Life Sciences will provide medical product research and development services to support the missions of the U.S. Army Medical Materiel Development Activity, U.S. Army Medical Materiel Agency, other subordinate commands of the U.S. Army Medical Research and Materiel Command, Joint Project Manager Medical Countermeasure Systems, and other Department of Defense (DoD) entities responsible for medical product research and development. Work under the contract is intended to support the entire scope of developing new drugs, vaccines, blood products, medical devices, and medical support equipment that enhances readiness, ensures the provision of the highest quality medical and preventive care to the DoD, and maximizes survival of medical casualties on the battlefield.
"Our Life Sciences team located in Frederick, Maryland, led by Dr. Jim Pannucci, has proudly supported the U.S. Army Medical Research and Material Command for more than 33 years," said Jerry Hogge, deputy group president of Leidos Federal Health. "Our distinguished scientists and researchers look forward to providing research and development for medical products to deliver solutions that can help save and improve the lives of our military service members."
Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 19,000 employees support vital missions for government and the commercial sector, develop innovative solutions to drive better outcomes and defend our digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.06 billion for its fiscal year ended January 30, 2015. For more information, visit www.Leidos.com.